共 89 条
[1]
Huang J(2021)Risk factors, patterns, and long-term survival of recurrence after radiofrequency ablation with or without transarterial chemoembolization for hepatocellular carcinoma Front Oncol 11 681-693
[2]
Huang W(2022)BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update J Hepatol 76 1359-1365
[3]
Guo Y(2018)Comparative effectiveness of transarterial embolization and sorafenib for hepatocellular carcinoma: a population-based study AJR Am J Roentgenol 210 1-7
[4]
Cai M(2022)Long-term outcomes of combined transarterial chemoembolization and radiofrequency ablation versus RFA monotherapy for single hepatocellular carcinoma ≤3 cm: emphasis on local tumor progression Int J Hyperthermia 39 1533-1543
[5]
Zhou J(2019)Chemoembolization combined with radiofrequency ablation for medium-sized hepatocellular carcinoma: a propensity-score analysis J Vasc Interv Radiol 30 1297-1308
[6]
Lin L(2022)A systematic review and meta-analysis on the efficacy and safety of transcatheter arterial chemoembolization combined with radiofrequency ablation in the treatment of primary liver cancer Transl Cancer Res 11 e0133488-248
[7]
Reig M(2015)Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional therapies: a literature-based meta-analysis PLoS ONE 10 242-890
[8]
Forner A(2015)Radiofrequency ablation plus drug-eluting beads transcatheter arterial chemoembolization for the treatment of single large hepatocellular carcinoma Dig Liver Dis 47 881-714
[9]
Rimola J(2016)Response to transarterial chemoembolization as a selection criterion for resection of hepatocellular carcinomas Br J Surg 103 162-669
[10]
Ferrer-Fàbrega J(2017)When and how should multiple imputation be used for handling missing data in randomised clinical trials - a practical guide with flowcharts BMC Med Res Methodol 17 705-1261